Empty pelvis syndrome as a cause of major morbidity after pelvic exenteration: validation of a core data set - Scorecard - MDSpire

Empty pelvis syndrome as a cause of major morbidity after pelvic exenteration: validation of a core data set

  • By

  • Charles T West

  • Abhinav Tiwari

  • Julian Smith

  • Hideaki Yano

  • Malcolm A West

  • Alex H Mirnezami

  • Southampton Complex Cancer and Exenteration Team

  • G Ansell

  • A Bateman

  • C Birch

  • L Borthwick

  • H Cheema

  • V Dawson

  • K Donovan

  • J Douglas

  • R Exton

  • B George

  • J Green

  • M Hayes

  • G Hodges

  • L Ingram

  • C Lane

  • R Lewis

  • T Nash

  • M Nicolaou

  • B Patterson

  • E Ryan

  • Y Salem

  • D Spencer

  • K Stoddard

  • P Tapley

  • L Wodd

  • R Zaher

  • April 30, 2025

  • 0 min

Share

Clinical Scorecard: Validation of a Core Data Set for Empty Pelvis Syndrome Following Pelvic Exenteration and Its Impact on Major Morbidity

At a Glance

CategoryDetail
ConditionEmpty Pelvis Syndrome (EPS) following Pelvic Exenteration (PE)
Key MechanismsPost-exenteration complications including infected pelvic collections, bowel obstruction, perineal sinus, and fistulae due to radical resection and bowel migration into pelvic void
Target PopulationPatients undergoing pelvic exenteration for advanced pelvic cancers
Care SettingSpecialized surgical oncology centers performing pelvic exenteration

Key Highlights

  • EPS occurred in 32.1% of patients and was the leading cause of major morbidity after PE.
  • Risk factors for EPS include external beam radiotherapy, sacrectomy, total cystectomy, internal iliac vessel ligation, and infralevator exenteration.
  • Omentoplasty reduced pelvic bowel obstruction, and biological mesh was associated with lower reconstruction-related morbidity compared to perineal flaps.

Guideline-Based Recommendations

Diagnosis

  • Use the PelvEx Collaborative core data set to standardize reporting and diagnosis of EPS manifestations.
  • Identify EPS by presence of infected pelvic collections, pelvic bowel obstruction, chronic perineal sinus, or enteroperineal fistula.

Management

  • Consider omentoplasty to reduce risk of pelvic bowel obstruction.
  • Use biological mesh for reconstruction to minimize reconstruction-related major morbidity compared to perineal flaps.
  • Recognize increased EPS risk with prior external beam radiotherapy and extensive resections such as sacrectomy and total cystectomy.

Monitoring & Follow-up

  • Follow patients at least yearly with clinical and radiological assessments to detect acute and chronic EPS complications.
  • Monitor for infected pelvic collections as they are associated with chronic sinus formation and fistula development.

Risks

  • Major morbidity from EPS is common and linked to radicality of surgery and prior radiotherapy.
  • Perineal flaps have higher reconstruction-related morbidity compared to biological mesh.
  • Infected pelvic collections increase risk of chronic sinus and fistula formation.

Patient & Prescribing Data

Patients undergoing pelvic exenteration for advanced pelvic malignancies

Omentoplasty and biological mesh use are associated with reduced EPS-related complications and reconstruction morbidity; risk stratification should consider prior radiotherapy and extent of resection.

Clinical Best Practices

  • Standardize EPS reporting using the PelvEx Collaborative core data set to improve research and clinical outcomes.
  • Employ omentoplasty routinely to mitigate pelvic bowel obstruction post-PE.
  • Prefer biological mesh over perineal flaps for pelvic reconstruction to reduce major morbidity.
  • Recognize and monitor high-risk patients with prior radiotherapy or extensive pelvic resections for early intervention.
  • Separate morbidity from reconstruction from EPS manifestations in clinical assessment.

References

Original Source(s)

Related Content